Spondyloarthritis & psoriatic arthritis
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis
Authors' conclusion
Across ASAS outcomes, bimekizumab was comparable with most b/tsDMARDs, including ixekizumab, TNF inhibitors and upadacitinib, and achieved higher response rates vs secukinumab for some ASAS outcomes in predominantly b/tsDMARD-naïve nr-axSpA and AS patients at 12-16 weeks. In a pooled axSpA network, bimekizumab demonstrated comparable safety vs other b/tsDMARDs.
Study context
- Population
- Patients with non-radiographic axial SpA (nr-axSpA) and AS in RCTs until January 202336 trials
- Comparison
- Bimekizumab 160 mg every 4 weeks vs other b/tsDMARDs
- Outcome
- ASAS20, ASAS40 and ASAS partial remission (PR) response rates
- Follow-up
- 12-16 weeks
Methodological detailsBayesian network meta-analysis, three b/tsDMARD exposure networks: predominantly-naïve, naïve, and experienced
- Bayesian network meta-analysis
- Three b/tsDMARD exposure networks: predominantly-naïve, naïve, and experienced
Pooled result
As reported in the abstract
ASAS response rates, predominantly-naïve networks
- nr-axSpA: bimekizumab significantly higher ASAS20 response rates vs secukinumab 150 mg (with loading dose (LD)/without LD)
- nr-axSpA: comparable response rates vs other active comparators
- AS: bimekizumab significantly higher ASAS40 response rates vs secukinumab 150 mg (without LD)
- AS: bimekizumab significantly higher ASAS-PR response rates vs secukinumab 150 mg (with LD)
- AS: comparable response rates vs other active comparators
- Bayesian NMA; predominantly-naïve network provided the most comprehensive results
Safety
Discontinuations due to any reason and serious adverse events · 12-16 weeks
- Bimekizumab demonstrated similar safety to that of other b/tsDMARDs
- Pooled axSpA network
Original publication
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). Published 8 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →